Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275533 | 0.89 | PDE10A (0.54) | SMOPDE10A | |
| SCHEMBL276023 | 0.88 | PDE10A (0.37) | SMOPDE10AMALT1GLP1RNPY5R | |
| SCHEMBL275614 | 0.87 | CNR2 (0.38) | SMOPDE10AGLP1RTRPV1 | |
| SCHEMBL276092 | 0.87 | GLP1R (0.38) | SMOPDE10AMALT1GLP1RSLC9A1 | |
| SCHEMBL275522 | 0.78 | GLP1R (0.38) | SMOPDE10AMALT1ALDH1A1MAPT | |
| SCHEMBL2373792 | 0.77 | NPC1 (0.42) | PDE10AALDH1A1MAPT | |
| SCHEMBL2232965 | 0.73 | ITGB3 (0.51) | SMOPDE10ATSHRMEN1ALDH1A1 | |
| SCHEMBL16334101 | 0.73 | ALDH1A1 (0.46) | PDE10ATSHRMEN1ALDH1A1MAPT | |
| SCHEMBL21832083 | 0.69 | KDM4E (0.47) | SMOPDE10AMEN1ALDH1A1KMT2A | |
| SCHEMBL20302549 | 0.68 | PDE10A (0.50) | SMOPDE10AALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198258-A1 | INTEGRIN ANTAGONISTS | Oxurion NV (BE) | 2021-07-01 | — | — | US | disclosed |
| US-20210198258-A1 | INTEGRIN ANTAGONISTS | Oxurion NV (BE) | 2021-07-01 | — | — | US | disclosed |
| CN-112805284-A | Integrin antagonists | 奥克斯润有限责任公司 | 2021-05-14 | — | — | CN | disclosed |
| EP-3613739-B1 | INTEGRIN ANTAGONISTS | Oxurion NV (BE) | 2020-11-04 | — | — | EP | disclosed |
| US-10703752-B2 | Integrin antagonists | Oxurion NV (BE) | 2020-07-07 | — | — | US | disclosed |
| US-10703752-B2 | Integrin antagonists | Oxurion NV (BE) | 2020-07-07 | — | — | US | disclosed |
| EP-3613739-A1 | INTEGRIN ANTAGONISTS | Oxurion NV (BE) | 2020-02-26 | — | — | EP | disclosed |
| US-20200055849-A1 | INTEGRIN ANTAGONISTS | Oxurion NV (BE) | 2020-02-20 | — | — | US | disclosed |
| US-20200055849-A1 | INTEGRIN ANTAGONISTS | Oxurion NV (BE) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198258-A1 | INTEGRIN ANTAGONISTS | ITGB1, ITGA2B, ITGA1 | SMO 1018/4885PDE10A 1987/4885TSHR 1506/4885 |
| US-10703752-B2 | Integrin antagonists | ITGB1, ITGA2B, ITGA1 | SMO 1043/4885PDE10A 2022/4885TSHR 1580/4885 |
| US-20200055849-A1 | INTEGRIN ANTAGONISTS | ITGB1, ITGA2B, ITGA1 | SMO 1043/4885PDE10A 2022/4885TSHR 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.